P16INK4A as a surrogate biomarker for human papillomavirus-associated oropharyngeal carcinoma: Consideration of some aspects

Cancer Science

Volumn 104, Issue 12, 2013, Pages 1553-1559

  Wang, Hongzhi ^a,b,c   Sun, Rui ^a,b,c   Lin, Hui ^d   Hu, Wei Han ^a,b,c  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^b State Key Laboratory of Oncology   (China)

^c Collaborative Innovation Center for Cancer Medicine   (China)

^d GUANGDONG PROVINCIAL PEOPLE'S HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; ANTINEOPLASTIC AGENT; CYCLIN D1; CYCLIN DEPENDENT KINASE INHIBITOR 2A; PHOSPHOPROTEIN PHOSPHATASE 2A; PROTEIN E6; PROTEIN E7; PROTEIN KINASE B; PROTEIN P53; VIRUS DNA; TUMOR MARKER;

ALCOHOL CONSUMPTION; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SURGERY; CELL PROLIFERATION; CHEMORADIOTHERAPY; DISEASE ASSOCIATION; DNA SYNTHESIS; ENZYME INHIBITION; FALSE NEGATIVE RESULT; FALSE POSITIVE RESULT; GENE DOSAGE; GENOMIC INSTABILITY; HISTOPATHOLOGY; HUMAN; HUMAN PAPILLOMAVIRUS DNA TEST; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; INDUCTION CHEMOTHERAPY; MOLECULAR PATHOLOGY; OROPHARYNX CARCINOMA; PAPILLOMAVIRUS INFECTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; SENSITIVITY AND SPECIFICITY; SMOKING; STAINING; TREATMENT RESPONSE; UPREGULATION; ALPHAPAPILLOMAVIRUS; GENETICS; METABOLISM; OROPHARYNX TUMOR; PATHOGENICITY; PROGNOSIS; VIROLOGY; COMPLICATION; OROPHARYNGEAL NEOPLASMS; PAPILLOMAVIRUS INFECTIONS;

ALPHAPAPILLOMAVIRUS; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DNA, VIRAL; HUMANS; OROPHARYNGEAL NEOPLASMS; PAPILLOMAVIRUS INFECTIONS; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84889583876     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/cas.12287     Document Type: Review

References (68)

1. Nobori T, Miura K, Wu DJ et al. Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature 1994; 368: 753-6.
2. Khleif SN, DeGregori J, Yee CL et al. Inhibition of cyclin D-CDK4/CDK6 activity is associated with an E2F-mediated induction of cyclin kinase inhibitor activity. Proc Natl Acad Sci U S A 1996; 93: 4350-4.
3. Dyson N, Howley PM, Munger K et al. The human papilloma virus-16 E7 oncoprotein is able to bind to the retinoblastoma gene product. Science 1989; 243: 934-7.
4. Munger K, Werness BA, Dyson N et al. Complex formation of human papillomavirus E7 proteins with the retinoblastoma tumor suppressor gene product. EMBO J 1989; 8: 4099-105.
5. Sano T, Oyama T, Kashiwabara K et al. Expression status of p16 protein is associated with human papillomavirus oncogenic potential in cervical and genital lesions. Am J Pathol 1998; 153: 1741-8.
6. Mulvany NJ, Allen DG, Wilson SM. Diagnostic utility of p16INK4a: a reappraisal of its use in cervical biopsies. Pathology 2008; 40: 335-44.
7. Carozzi F, Gillio-Tos A, Confortini M et al. Risk of high-grade cervical intraepithelial neoplasia during follow-up in HPV-positive women according to baseline p16-INK4A results: a prospective analysis of a nested substudy of the NTCC randomised controlled trial. Lancet Oncol 2013; 14: 168-76.
8. Nishio S, Fujii T, Nishio H et al. p16(INK4a) immunohistochemistry is a promising biomarker to predict the outcome of low grade cervical intraepithelial neoplasia: comparison study with HPV genotyping. J Gynecol Oncol 2013; 24: 215-21.
9. Shi W, Kato H, Perez-Ordonez B et al. Comparative prognostic value of HPV16 E6 mRNA compared with in situ hybridization for human oropharyngeal squamous carcinoma. J Clin Oncol 2009; 27: 6213-21.
10. Reimers N, Kasper HU, Weissenborn SJ et al. Combined analysis of HPV-DNA, p16 and EGFR expression to predict prognosis in oropharyngeal cancer. Int J Cancer 2007; 120: 1731-8.
11. Smeets SJ, Hesselink AT, Speel EJ et al. A novel algorithm for reliable detection of human papillomavirus in paraffin embedded head and neck cancer specimen. Int J Cancer 2007; 121: 2465-72.
12. Licitra L, Perrone F, Bossi P et al. High-risk human papillomavirus affects prognosis in patients with surgically treated oropharyngeal squamous cell carcinoma. J Clin Oncol 2006; 24: 5630-6.
13. Fakhry C, Westra WH, Li S et al. Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. J Natl Cancer Inst 2008; 100: 261-9.
14. Weinberger PM, Yu Z, Haffty BG et al. Molecular classification identifies a subset of human papillomavirus-associated oropharyngeal cancers with favorable prognosis. J Clin Oncol 2006; 24: 736-47.
15. von Knebel DM. New markers for cervical dysplasia to visualise the genomic chaos created by aberrant oncogenic papillomavirus infections. Eur J Cancer 2002; 38: 2229-42.
16. Kreimer AR, Clifford GM, Boyle P et al. Human papillomavirus types in head and neck squamous cell carcinomas worldwide: a systematic review. Cancer Epidemiol Biomarkers Prev 2005; 14: 467-75.
17. Marur S, D'Souza G, Westra WH et al. HPV-associated head and neck cancer: a virus-related cancer epidemic. Lancet Oncol 2010; 11: 781-9.
18. Gillison ML, D'Souza G, Westra W et al. Distinct risk factor profiles for human papillomavirus type 16-positive and human papillomavirus type 16-negative head and neck cancers. J Natl Cancer Inst 2008; 100: 407-20.
19. Smith EM, Ritchie JM, Summersgill KF et al. Age, sexual behavior and human papillomavirus infection in oral cavity and oropharyngeal cancers. Int J Cancer 2004; 108: 766-72.
20. Gillison ML, Koch WM, Capone RB et al. Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. J Natl Cancer Inst 2000; 92: 709-20.
21. Nasman A, Andersson E, Nordfors C et al. MHC class I expression in HPV positive and negative tonsillar squamous cell carcinoma in correlation to clinical outcome. Int J Cancer 2013; 132: 72-81.
22. Lewis JJ, Thorstad WL, Chernock RD et al. p16 positive oropharyngeal squamous cell carcinoma:an entity with a favorable prognosis regardless of tumor HPV status. Am J Surg Pathol 2010; 34: 1088-96.
23. Hong AM, Dobbins TA, Lee CS et al. Human papillomavirus predicts outcome in oropharyngeal cancer in patients treated primarily with surgery or radiation therapy. Br J Cancer 2010; 103: 1510-7.
24. Thavaraj S, Stokes A, Guerra E et al. Evaluation of human papillomavirus testing for squamous cell carcinoma of the tonsil in clinical practice. J Clin Pathol 2011; 64: 308-12.
25. Evans MF, Matthews A, Kandil D et al. Discrimination of 'driver' and 'passenger' HPV in tonsillar carcinomas by the polymerase chain reaction, chromogenic in situ hybridization, and p16(INK4a) immunohistochemistry. Head Neck Pathol 2011; 5: 344-8.
26. Junor E, Kerr G, Oniscu A et al. Benefit of chemotherapy as part of treatment for HPV DNA-positive but p16-negative squamous cell carcinoma of the oropharynx. Br J Cancer 2012; 106: 358-65.
27. Jordan RC, Lingen MW, Perez-Ordonez B et al. Validation of methods for oropharyngeal cancer HPV status determination in US cooperative group trials. Am J Surg Pathol 2012; 36: 945-54.
28. Holzinger D, Schmitt M, Dyckhoff G et al. Viral RNA patterns and high viral load reliably define oropharynx carcinomas with active HPV16 involvement. Cancer Res 2012; 72: 4993-5003.
29. Gao G, Chernock RD, Gay HA et al. A novel RT-PCR method for quantification of human papillomavirus transcripts in archived tissues and its application in oropharyngeal cancer prognosis. Int J Cancer 2013; 132: 882-90.
30. Hong A, Jones D, Chatfield M et al. HPV status of oropharyngeal cancer by combination HPV DNA/p16 testing: biological relevance of discordant results. Ann Surg Oncol 2012; doi:10.1245/s10434-012-2778-4. [Epub ahead of print].
31. El-Naggar AK, Westra WH. p16 expression as a surrogate marker for HPV-related oropharyngeal carcinoma: a guide for interpretative relevance and consistency. Head Neck 2012; 34: 459-61.
32. Cui SP, Wang HL, Peng W et al. Aberrant expression and correlative analysis of P16 in breast cancers. Beijing Da Xue Xue Bao 2012; 44: 755-9.
33. Yuan J, Knorr J, Altmannsberger M et al. Expression of p16 and lack of pRB in primary small cell lung cancer. J Pathol 1999; 189: 358-62.
34. Klingenberg B, Hafkamp HC, Haesevoets A et al. p16 INK4A overexpression is frequently detected in tumour-free tonsil tissue without association with HPV. Histopathology 2010; 56: 957-67.
35. Hoffmann M, Ihloff AS, Gorogh T et al. p16(INK4a) overexpression predicts translational active human papillomavirus infection in tonsillar cancer. Int J Cancer 2010; 127: 1595-602.
36. Jung AC, Briolat J, Millon R et al. Biological and clinical relevance of transcriptionally active human papillomavirus (HPV) infection in oropharynx squamous cell carcinoma. Int J Cancer 2010; 126: 1882-94.
37. Chung CH, Gillison ML. Human papillomavirus in head and neck cancer: its role in pathogenesis and clinical implications. Clin Cancer Res 2009; 15: 6758-62.
38. Schache AG, Liloglou T, Risk JM et al. Evaluation of human papilloma virus diagnostic testing in oropharyngeal squamous cell carcinoma: sensitivity, specificity, and prognostic discrimination. Clin Cancer Res 2011; 17: 6262-71.
39. Bishop JA, Ma XJ, Wang H et al. Detection of transcriptionally active high-risk HPV in patients with head and neck squamous cell carcinoma as visualized by a novel E6/E7 mRNA in situ hybridization method. Am J Surg Pathol 2012; 36: 1874-82.
40. Ukpo OC, Flanagan JJ, Ma XJ et al. High-risk human papillomavirus E6/E7 mRNA detection by a novel in situ hybridization assay strongly correlates with p16 expression and patient outcomes in oropharyngeal squamous cell carcinoma. Am J Surg Pathol 2011; 35: 1343-50.
41. Rotnaglova E, Tachezy R, Salakova M et al. HPV involvement in tonsillar cancer: prognostic significance and clinically relevant markers. Int J Cancer 2011; 129: 101-10.
42. Duray A, Descamps G, Arafa M et al. High incidence of high-risk HPV in benign and malignant lesions of the larynx. Int J Oncol 2011; 39: 51-9.
43. Schlecht NF, Brandwein-Gensler M, Nuovo GJ et al. A comparison of clinically utilized human papillomavirus detection methods in head and neck cancer. Mod Pathol 2011; 24: 1295-305.
44. Ha PK, Pai SI, Westra WH et al. Real-time quantitative PCR demonstrates low prevalence of human papillomavirus type 16 in premalignant and malignant lesions of the oral cavity. Clin Cancer Res 2002; 8: 1203-9.
45. Combita AL, Bravo MM, Touze A et al. Serologic response to human oncogenic papillomavirus types 16, 18, 31, 33, 39, 58 and 59 virus-like particles in colombian women with invasive cervical cancer. Int J Cancer 2002; 97: 796-803.
46. Mork J, Lie AK, Glattre E et al. Human papillomavirus infection as a risk factor for squamous-cell carcinoma of the head and neck. N Engl J Med 2001; 344: 1125-31.
47. Dahlstrom KR, Adler-Storthz K, Etzel CJ, et al. Human papillomavirus type 16 infection and squamous cell carcinoma of the head and neck in never-smokers: a matched pair analysis. Clin Cancer Res 2003; 9: 2620-6.
48. Rayess H, Wang MB, Srivatsan ES. Cellular senescence and tumor suppressor gene p16. Int J Cancer 2012; 130: 1715-25.
49. Dahlgren L, Mellin H, Wangsa D et al. Comparative genomic hybridization analysis of tonsillar cancer reveals a different pattern of genomic imbalances in human papillomavirus-positive and -negative tumors. Int J Cancer 2003; 107: 244-9.
50. Agrawal N, Frederick MJ, Pickering CR et al. Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1. Science 2011; 333: 1154-7.
51. Heath S, Willis V, Allan K et al. Clinically significant human papilloma virus in squamous cell carcinoma of the head and neck in UK practice. Clin Oncol (R Coll Radiol) 2012; 24: e18-23.
52. Holzinger D, Flechtenmacher C, Henfling N et al. Identification of oropharyngeal squamous cell carcinomas with active HPV16 involvement by immunohistochemical analysis of the retinoblastoma protein pathway. Int J Cancer 2013; 133: 1389-99.
53. Bosch FX, Ritter D, Enders C et al. Head and neck tumor sites differ in prevalence and spectrum of p53 alterations but these have limited prognostic value. Int J Cancer 2004; 111: 530-8.
54. Mannweiler S, Sygulla S, Winter E et al. Two major pathways of penile carcinogenesis: HPV-induced penile cancers overexpress p16ink4a, HPV-negative cancers associated with dermatoses express p53, but lack p16ink4a overexpression. J Am Acad Dermatol 2013; 69: 73-81.
55. Rainsbury JW, Ahmed W, Williams HK et al. Prognostic biomarkers of survival in oropharyngeal squamous cell carcinoma: systematic review and meta-analysis. Head Neck 2013; 35: 1048-55.
56. Ang KK, Harris J, Wheeler R et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med 2010; 363: 24-35.
57. Rischin D, Young RJ, Fisher R et al. Prognostic significance of p16INK4A and human papillomavirus in patients with oropharyngeal cancer treated on TROG 02.02 phase III trial. J Clin Oncol 2010; 28: 4142-8.
58. Lassen P, Eriksen JG, Hamilton-Dutoit S et al. Effect of HPV-associated p16INK4A expression on response to radiotherapy and survival in squamous cell carcinoma of the head and neck. J Clin Oncol 2009; 27: 1992-8.
59. Cohen MA, Weinstein GS, O'Malley BJ et al. Transoral robotic surgery and human papillomavirus status: Oncologic results. Head Neck 2011; 33: 573-80.
60. Lassen P. The role of human papillomavirus in head and neck cancer and the impact on radiotherapy outcome. Radiother Oncol 2010; 95: 371-80.
61. Lassen P, Eriksen JG, Hamilton-Dutoit S et al. HPV-associated p16-expression and response to hypoxic modification of radiotherapy in head and neck cancer. Radiother Oncol 2010; 94: 30-5.
62. Mehra R, Ang KK, Burtness B. Management of human papillomavirus-positive and human papillomavirus-negative head and neck cancer. Semin Radiat Oncol 2012; 22: 194-7.
63. Pim D, Massimi P, Dilworth SM et al. Activation of the protein kinase B pathway by the HPV-16 E7 oncoprotein occurs through a mechanism involving interaction with PP2A. Oncogene 2005; 24: 7830-8.
64. Overgaard J, Eriksen JG, Nordsmark M et al. Plasma osteopontin, hypoxia, and response to the hypoxia sensitiser nimorazole in radiotherapy of head and neck cancer: results from the DAHANCA 5 randomised double-blind placebo-controlled trial. Lancet Oncol 2005; 6: 757-64.
65. Song S, Gulliver GA, Lambert PF. Human papillomavirus type 16 E6 and E7 oncogenes abrogate radiation-induced DNA damage responses in vivo through p53-dependent and p53-independent pathways. Proc Natl Acad Sci U S A 1998; 95: 2290-5.
66. Duensing S, Munger K. Mechanisms of genomic instability in human cancer: insights from studies with human papillomavirus oncoproteins. Int J Cancer 2004; 109: 157-62.
67. Wansom D, Light E, Worden F et al. Correlation of cellular immunity with human papillomavirus 16 status and outcome in patients with advanced oropharyngeal cancer. Arch Otolaryngol Head Neck Surg 2010; 136: 1267-73.
68. Martinez I, Wang J, Hobson KF et al. Identification of differentially expressed genes in HPV-positive and HPV-negative oropharyngeal squamous cell carcinomas. Eur J Cancer 2007; 43: 415-32.